-+ 0.00%
-+ 0.00%
-+ 0.00%

Reviva Pharmaceuticals stock faces Nasdaq delisting after failing $1 minimum bid requirement

PUBT·05/13/2026 12:06:28
Listen to the news
Reviva Pharmaceuticals stock faces Nasdaq delisting after failing $1 minimum bid requirement
  • Reviva Pharmaceuticals stock set for Nasdaq suspension at open May 14, 2026, following Nasdaq Hearings Panel decision to delist for failing to regain compliance with Nasdaq Listing Rule 5550(a)(2) minimum $1 bid price by May 11, 2026.
  • Quotation to move to OTCQB Venture Market on May 14, 2026 under existing symbol RVPH.
  • Shift off Nasdaq expected to pressure liquidity, widen volatility, and constrain access to equity financing as shares fall under penny stock rules.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reviva Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-016538), on May 13, 2026, and is solely responsible for the information contained therein.